ASTRAZENECA PLC-SPONS ADR (AZN)       65.53  -0.46 (-0.7%)

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire and currently employs 83,100 full-time employees. The company went IPO on 2007-09-21. The firm focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 179 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia. The company is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.

Company Info

ASTRAZENECA PLC-SPONS ADR

1 Francis Crick Avenue

Cambridge CAMBRIDGESHIRE CB2 0AA

P: 442073045000.0

CEO: Pascal Soriot

Employees: 83100

Website: https://www.astrazeneca.com/Home